1. Home
  2. CLLS vs TCI Comparison

CLLS vs TCI Comparison

Compare CLLS & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • TCI
  • Stock Information
  • Founded
  • CLLS 1999
  • TCI 1983
  • Country
  • CLLS France
  • TCI United States
  • Employees
  • CLLS N/A
  • TCI N/A
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • TCI Real Estate
  • Sector
  • CLLS Health Care
  • TCI Finance
  • Exchange
  • CLLS Nasdaq
  • TCI Nasdaq
  • Market Cap
  • CLLS 240.2M
  • TCI 239.2M
  • IPO Year
  • CLLS 2007
  • TCI N/A
  • Fundamental
  • Price
  • CLLS $1.98
  • TCI $28.25
  • Analyst Decision
  • CLLS Buy
  • TCI
  • Analyst Count
  • CLLS 2
  • TCI 0
  • Target Price
  • CLLS $8.00
  • TCI N/A
  • AVG Volume (30 Days)
  • CLLS 19.9K
  • TCI 2.7K
  • Earning Date
  • CLLS 11-04-2024
  • TCI 11-07-2024
  • Dividend Yield
  • CLLS N/A
  • TCI N/A
  • EPS Growth
  • CLLS N/A
  • TCI N/A
  • EPS
  • CLLS N/A
  • TCI 0.69
  • Revenue
  • CLLS $19,635,000.00
  • TCI $50,541,000.00
  • Revenue This Year
  • CLLS $271.02
  • TCI N/A
  • Revenue Next Year
  • CLLS $33.48
  • TCI N/A
  • P/E Ratio
  • CLLS N/A
  • TCI $41.06
  • Revenue Growth
  • CLLS N/A
  • TCI N/A
  • 52 Week Low
  • CLLS $0.96
  • TCI $26.91
  • 52 Week High
  • CLLS $3.77
  • TCI $43.40
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 34.12
  • TCI 46.70
  • Support Level
  • CLLS $1.95
  • TCI $28.22
  • Resistance Level
  • CLLS $2.25
  • TCI $28.69
  • Average True Range (ATR)
  • CLLS 0.12
  • TCI 0.63
  • MACD
  • CLLS -0.04
  • TCI 0.05
  • Stochastic Oscillator
  • CLLS 6.67
  • TCI 58.82

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

Share on Social Networks: